174 patents
Utility
Methods of Treating Patients Having Complement Disorders Using ANTI-C5 Antibodies
18 Jan 24
Provided herein are methods of treatment designed to prevent or minimize formation of deleterious multivalent immune complexes in a human patient having a complement mediated disorder (e.g., paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS)), who has been or is being treated with a first anti-C5 antibody and is then treated with a second (different) anti-C5 antibody, as well as methods of safely switching a patient from treatment with a first anti-C5 antibody to a second (different) anti-C5 antibody.
Krista K. Johnson, Paul P. Tamburini, Douglas L. Sheridan
Filed: 22 Oct 21
Utility
Methods of Treating Copper Metabolism-associated Diseases or Disorders
28 Dec 23
This disclosure relates to methods of diagnosing and treating a copper metabolism-associated disease or disorder, such as Wilson disease (WD).
Pan Wei-Jian, Mark Ma, Brian Meltzer, Eugene Scott Swenson, Scott Edward Mosley, Ryan Pelto, Adam Quicquaro, Guillermo del Angel, Hareesh Chamarthi
Filed: 12 Nov 21
Utility
Methods for Treating a Complement Mediated Disorder Caused by Viruses
28 Dec 23
The present disclosure relates to, inter alia, a method of treating a complement mediated disorder caused by a virus, e.g., corona virus; Dengue virus (DENY); Ross River vims (RRV) and/or influenza virus (flu) by administering an effective amount of a complement modulator, such as, e.g., C5 inhibitor, such as eculizumab or an eculizumab variant or a C5a inhibitor such as olendalizumab (ALXN1007) or a variant thereof, to the subject.
Sharon Barr, Derek Dunn, Xiang Gao, Shamsah D. Kazani, Michele Mercuri, Jonathan Monteleone, Stephan Ortiz, Scott T. Rottinghaus, Martine Zimmermann, Djillali Annane, Veronique Fremeaux-Bacchi, Regis Peffault De Latour
Filed: 16 Apr 21
Utility
Preparation of factor Xa derivatives
19 Dec 23
The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product.
Mark Karbarz, Pamela B. Conley, Genmin Lu
Filed: 9 Mar 21
Utility
Antidotes for factor Xa inhibitors and methods of using the same
12 Dec 23
The present invention relates antidotes to anticoagulants targeting factor Xa.
Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
Filed: 7 May 20
Utility
Process for Making Recombinant Antidote to Factor Xa Inhibitor
30 Nov 23
Disclosed are methods and isolated cells useful for the improved production of function fXa derivative protein that acts as a fXa inhibitor antidote.
Genmin Lu, Pamela B. Conley, Uma Sinha
Filed: 22 Mar 23
Utility
Method of quantitating unbound C5a in a sample
28 Nov 23
A method of quantitating free (unbound) human C5a complement protein (C5a) from a sample comprising: binding biotinylated anti-C5a capture antibody to strepavidin-coated particles; capturing the free (unbound) C5 in the sample; detecting the captured free C5a; and quantitating the captured free C5 using laser-induced fluorescence detection; wherein the method is performed in a Gyros Bioaffy 200 CD in a Gyrolab xPlore or a Gyrolab XP instrument; wherein human C5 is first removed from the sample.
Mark Dysinger, Mark Ma
Filed: 19 Oct 17
Utility
Methods for Treating Bone Mineralization Disorders
23 Nov 23
Featured are compositions and methods for treating bone mineralization disorders, such as hypophosphatasia (HPP).
Anna Petryk, Loredana Cuccia
Filed: 2 Sep 21
Utility
Methods of Treating Dermatomyositis
9 Nov 23
The disclosure provides methods of treating a subject having or suspected of having dermatomyositis using a composition including a bi-specific fusion protein.
Paul P. Tamburini
Filed: 5 Oct 21
Utility
Methods and compositions for treating complement-associated disorders
7 Nov 23
The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders.
Russell P. Rother
Filed: 20 Mar 19
Utility
Method for Treating Complement Mediated Disorders Caused by Betacoronaviruses
2 Nov 23
The present disclosure provides methods and compositions useful for diagnosing and treating activated alternative pathway of complement in a human subject with a SARS-CoV-2 infection.
Moshe Vardi, Robert A. Brodsky, Xiang Gao, Shamsah D. Kazani, Venu Nagali, Xuan Yuan
Filed: 27 Aug 21
Utility
Dosage and Administration of ANTI-C5 Antibodies for Treating C5-MEDIATED Glomerular Nephritis (GN), Including Lupus Nephritis (LN) And/or Iga Nephropathy (Igan)
2 Nov 23
Provided are dosages and methods for clinical treatment of C5-mediated glomerular nephritis (GN), including lupus nephritis (LN) and immunoglobulin A nephropathy (IgAN), in human patients using an anti C5 antibody, or antigen binding fragment thereof (e.g., such as ravulizumab (ULTOMIRIS®)), optionally together with background therapy for treating LN (e.g., an immuno-suppressant) or background therapy for treating IgAN (e.g., renin-angiotensin system (RAS) inhibiting medication).
Nader Najafian
Filed: 16 Sep 21
Utility
Method of Using Extracellular Vesicles to Detect Complement Activation, and Uses Thereof to Assess And/or Monitor Treatment of a Complement-mediated Disease
2 Nov 23
Disclosed herein are methods of detecting complement activity in a biological sample.
Ellen E. Millman, Tobin J. Cammett
Filed: 13 May 21
Utility
Humanized anti-CD200 antibodies and uses thereof
31 Oct 23
Provided herein are antibodies, or antigen binding portions thereof, that bind to CD200.
Taneisha Ann-Tanara Mack, Douglas L. Sheridan, Tadas Panavas
Filed: 20 Dec 18
Utility
Subcutaneous (SC) Administration of ANTI-C5 Antibodies for Treatment of Complement-associated Conditions
28 Sep 23
Provided are methods for clinical treatment of complement-associated conditions comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) subcutaneously according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule).
Dino C. Miano, Hweirung Amy Wang, Tatyana Mezhebovsky
Filed: 6 May 21
Utility
Biomarker signature for predicting tumor response to anti-CD200 therapy
19 Sep 23
Provided herein are methods for treating cancer in a patient who has been determined to have positive expression of CD200 receptor (CD200R1) and one or more biomarkers (i.e., ICOS, TIGIT, TNFRSF9, HAVCR2, PDCD1, FCGR2A, FCGR1A, CD163, and/or CD14) by administering to the patient a CD200 inhibitor.
Rui-Ru Ji, Mark Hamilton, Sharon Barr
Filed: 26 Sep 18
Utility
High Concentration ANTI-C5 Antibody Formulations
17 Aug 23
The present disclosure relates to stable aqueous solutions comprising a high concentration of an anti-05 antibody (e.g., ravulizumab) and methods for preparing the solutions.
Stephan ORTIZ, Jillian GENTILE, Leena PHILOMINATHAN, Eric ROUTHIER, Bruce MASON
Filed: 21 Dec 22
Utility
Solid forms of Cerdulatinib
1 Aug 23
Forms of cerdulatinib and salts or co-crystals thereof were prepared and characterized in the solid state.
Anjali Pandey, Julian Scott Northen, Philippe Fernandes, Ying Chen, Yuelie Lu, Sami Karaborni, Gus Kodersha
Filed: 16 Nov 20
Utility
Polypeptides That Bind Complement Component C5 or Serum Albumin and Fusion Proteins Thereof
27 Jul 23
The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin.
Bridget PUFFER, Julian CHANDLER, Nimish GERA, Douglas L. SHERIDAN, Siddharth JINDAL, Paul P. TAMBURINI
Filed: 7 Oct 22
Utility
Dosage and Administration of ANTI-C5 Antibodies for Treating Paroxysmal Nocturnal Hemoglobinuria (PNH) In Pediatric Patients
27 Jul 23
Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in pediatric patients using an anti-C5 antibody, or antigen binding fragment thereof.
Lori Payton, Scott T. Rottinghaus, Rajendra Pradhan, Stephan Ortiz, Masayo Ogawa, Xiang Gao
Filed: 8 Jul 21